Treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL Pulmonary-Allergy Drug Advisory Committee voted 10 to 3 in favor of a new indication for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema and to reduce exacerbations in COPD patients.
Agents scheduled for review by an FDA advisory panel
Testosterone replacement therapy Various Review of adverse cardiovascular outcomes associated with the use of testosterone replacement therapy 
WARNINGS AND PRECAUTIONS Patient Selection
• Proper patient selection is critical to the safe and effective use of Symlin. Before initiating Symlin, the patient's HbA1c, recent blood glucose monitoring data, history of insulininduced hypoglycemia, current insulin regimen, and body weight should be reviewed. Symlin therapy should only be considered in patients with type 1 diabetes or patients with type 2 diabetes using mealtime insulin who fulfi ll the following criteria... Hypoglycemia
• Symlin alone does not cause hypoglycemia. However, Symlin is indicated to be coadministered with mealtime insulin therapy, and in this setting there is an increased risk of severe hypoglycemia, particularly in patients with type 1 diabetes. If severe hypoglycemia associated with Symlin occurs, it is usually seen within the fi rst 2 to 3 hours following a Symlin injection. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ ucm123372.htm Ruxolitinib Jakafi (Incyte Corporation)
WARNINGS AND PRECAUTIONS Risk of Infection Tuberculosis
• Tuberculosis infection has been reported in patients receiving Jakafi . Myelofi brosis Symptom Exacerbation Following Interruption or Discontinuation of Treatment with Jakafi
• Following discontinuation of Jakafi , symptoms of myelofi brosis generally return to pretreatment levels over a period of approximately 1 week. Some patients have experienced 1 or more of the following adverse events after discontinuing Jakafi : fever, respiratory distress, hypotension, DIC, or multi-organ failure. If one or more of these occur after discontinuation of, or while tapering the dose of Jakafi , evaluate for and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi . Instruct patients not to interrupt or discontinue Jakafi therapy without consulting their physician. When discontinuing or interrupting therapy with Jakafi for reasons other than thrombocytopenia or neutropenia consider tapering the dose of Jakafi gradually rather than discontinuing abruptly. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm377314.htm Somatropin (rDNA origin) Humatrope for injection (Eli Lilly and Company)
WARNINGS AND PRECAUTIONS Neoplasms
• In childhood cancer survivors who were treated with radiation to the brain/head for their fi rst neoplasm and who developed subsequent GH defi ciency and were treated with somatropin, an increased risk of a second neoplasm has been reported. Intracranial tumors, in particular meningiomas, were the more common of these second neoplasms. In adults, it is unknown whether there is any relationship between somatropin replacement therapy and CNS tumor recurrence. 
• In childhood cancer survivors who were treated with radiation to the brain/head for their fi rst neoplasm and who developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm has been reported. Intracranial tumors, in particular meningiomas, were the more common of these second neoplasms. In adults, it is unknown whether there is any relationship between somatropin replacement therapy and CNS tumor recurrence. • Monitor all patients with a history of GHD secondary to an intracranial neoplasm routinely while on somatropin therapy for progression or recurrence of the tumor. • Because children with certain rare genetic causes of short stature have an increased risk of developing malignancies, practitioners should thoroughly consider the risks and benefi ts of starting somatropin in these patients. 
